Ensure continuity of patient care with fast and fully automated screening of DR

iCare’s winning combination of devices and software solutions supports enhanced diagnosis and management of diabetic retinopathy (DR), and continuity of patient care. Cutting-edge imaging devices capture high-quality, retinal images and an advanced AI platform can help scale up and automate retinal screening programs efficiently.

The number of adults with diabetes has more than tripled over the past 20 years, to over 450 million people

The fear of losing sight is widespread among patients with diabetes, with one out of three people developing diabetic retinopathy, the leading cause of severe vision loss and blindness. The scale and convenience of retinal screening programs are key success factors to help keep up the pace with future needs.

Diabetic clinics and primary care centers can now easily screen the condition of each patient’s retina efficiently, thanks to iCare’s integrated system of imaging devices and AI-based screening software. With smart tools supporting the early detection of DR retinopathy, patients receive timely care, and screening programs can be scaled up efficiently to reach out to more people.

Ensuring optimal patient care by combining cutting-edge imaging devices and AI solutions

With iCare ILLUME, AI-assisted DR screenings can be easily integrated into a clinical practice, helping healthcare professionals ensure the condition of every patient, without having to redirect them from the ongoing care pathway.

Capture high-quality retinal images with ease and accuracy

iCare DRSplus is equipped with TrueColor Confocal Technology to capture high-quality retinal images with ease and accuracy to help support the early diagnosis of diabetic retinopathy. iCare ILLUME uses a trusted partner’s specialized AI-based screening technology that automatically detects early signs of disease and classifies the results according to severity.

Improved efficiency

The automated workflow enables fast, efficient, and cost-effective screenings, making them scalable and sustainable over time. This improved efficiency can aid in the early detection of diabetic retinopathy, which can also decrease the workload and cost demands of eye screening programs. This is especially crucial for healthcare systems with varying income levels, making the screenings more accessible and sustainable.

Easy screening solution for a seamless clinical experience for both professionals and patients

The screening process with the iCare ILLUME is not only quick and convenient for professionals, but also patient friendly.

The DRSplus retinal camera uses proprietary technology that eliminates the need to use drops for dilation— images can be taken even if patients have cataracts. This ensures that patients have successful screening tests on the first take, making the process smooth for patients and professionals.

Patients get the advantage of results delivered in under five minutes facilitating immediate discussions about the findings during a routine clinical visit, ensuring uninterrupted patient care.

Bringing efficiency to retinal screening programs to help facilitate timely treatment

Regular screenings are essential for patients diagnosed with diabetes, especially patients with type 1 diabetes. Many national associations recommend a goal of annual diabetic retinopathy examinations for patients with either type 1 or type 2 diabetes.

Effective treatment options for preventing or significantly slowing vision loss

The primary motivation for screening is that there are now effective treatment options for preventing or significantly slowing vision loss, making timely intervention vital. Moreover, when patients have the opportunity to view the screening results during regular check-ups, it can enhance their commitment to the treatment.

The ILLUME solution

Adding artificial intelligence (AI) in the initial diabetic retinopathy screening phase promises to vastly increase the efficiency and effectiveness of screening programs. Researchers have suggested that with AI-assisted screening for referable diabetic retinopathy, existing eye healthcare resources could easily accommodate the expected demand for screening, worldwide.

The ILLUME solution ultimately helps ensure continuity of care for patients with diabetes as they move through the healthcare system.